China’s Neurophth Therapeutics, which develops in-vivo gene therapies for ophthalmic diseases, announced on Wednesday the completion of its Series C+ funding round at almost 700 million yuan ($97.7 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
